Inhibitors of angiogenic factors
AssigneeEluminex Biosciences (Suzhou) Limited
InventorsJinzhong ZHANG, Wei Yong SHEN, Charles SEMBA, John Zhenze HU, Zhen Qin XIA
Life of this patent
Estimating the term…
Abstract
A recombinant human Fc fusion protein comprises an Ig-like domain of a first human VEGF receptor, another different Ig-like domain of a second human VEGF receptor, at least yet another Ig-like domain of a third human VEGF receptor, and the Fc portion of the human IgG1. The fusion protein is useful in treating or controlling an ocular disease, condition, or disorder that has etiology in aberrant angiogenesis.
Claims28
A recombinant human Fc fusion protein, comprising an Ig-like domain of a first VEGF receptor, an Ig-like domain of a second VEGF receptor, and at least an Ig-like domain of a third VEGF receptor;
- wherein said third VEGF receptor comprises human VEGFR-3 (flt-4) having an amino acid sequence listed in SEQ ID NO:
- 13 with the proviso that the amino acids at positions 105 and 106 of SEQ ID NO:
- 13 are substitutable such that the amino acid sequence at positions 104-106 of SEQ ID NO:
- 13 is NDT, NDS, NXT, or NXS, wherein X is an amino acid selected from the group consisting of A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, and V.
(canceled)
(canceled)
A fusion protein comprising an amino acid sequence that is at least 95% identical to the amino acid sequence listed in SEQ ID NO:
- 12 with the proviso that the amino acids at positions 286 and 287 of SEQ ID NO:
- 12 are substitutable such that the amino acid sequence at positions 285-287 of SEQ ID NO:
- 12 is NDT, NDS, NXT, or NXS, wherein X is an amino acid selected from the group consisting of A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, and V.
(canceled)
(canceled)
A method for treating or controlling at least a disease, condition, or disorder, in a subject in need thereof, which has etiology in aberrant angiogenesis;
- said method comprising administering to said subject an amount of a composition of a fusion protein comprising an amino acid sequence that is at least 95% identical to the amino acid sequence listed in SEQ ID NO:
- 12 or SEQ ID NO:
- 16 with the proviso that the amino acids at positions 286 and 287 of SEQ ID NO:
- 12 or SEQ ID NO:
- 16 are substitutable such that the amino acid sequence at positions 285-287 of SEQ ID NO:
- 12 or SEQ ID NO:
- 16 is NDT, NDS, NXT, or NXS, wherein X is an amino acid selected from the group consisting of A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, and V.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.